Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer

Dendritic cells (DCs), the strongest antigen-presenting cells, are a focus for orchestrating the immune system in the fight against cancer. Basic scientific investigations elucidating the cellular biology of the DCs have resulted in new strategies in this fight, including cancer vaccinology, combina...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 887189
Main Author Ni, Ling
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 10.05.2022
Subjects
Dendritic Cells
gastrointestinal cancers
Gastrointestinal Neoplasms - therapy
Humans
Immunology
immunotherapy
Immunotherapy - methods
Immunotherapy, Adoptive
patients
vaccines
gastrointestinal cancers
dendritic cells
vaccines
immunotherapy
patients
Online AccessGet full text

Cover

More Information
Summary:Dendritic cells (DCs), the strongest antigen-presenting cells, are a focus for orchestrating the immune system in the fight against cancer. Basic scientific investigations elucidating the cellular biology of the DCs have resulted in new strategies in this fight, including cancer vaccinology, combination therapy, and adoptive cellular therapy. Although immunotherapy is currently becoming an unprecedented bench-to-bedside success, the overall response rate to the current immunotherapy in patients with gastrointestinal (GI) cancers is pretty low. Here, we have carried out a literature search of the studies of DCs in the treatment of GI cancer patients. We provide the advances in DC-based immunotherapy and highlight the clinical trials that indicate the therapeutic efficacies and toxicities related with each vaccine. Moreover, we also offer the yet-to-be-addressed questions about DC-based immunotherapy. This study focuses predominantly on the data derived from human studies to help understand the involvement of DCs in patients with GI cancers.
Bibliography:Reviewed by: Daniel Benitez-Ribas, Hospital Clínic de Barcelona, Spain; Yunbin Ye, Fujian Cancer Hospital, China
Edited by: Manel Juan, Hospital Clínic de Barcelona, Spain
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.887189